You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
|
|---|---|
| Published in |
Journal of Hematology & Oncology, April 2016
|
| DOI | 10.1186/s13045-016-0268-z |
| Pubmed ID | |
| Authors |
Shuhang Wang, Shundong Cang, Delong Liu |
| Abstract |
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M mutation have been in active clinical development. These agents include osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775. Osimertinib and rociletinib have shown clinical efficacy in phase I/II trials in patients who had acquired resistance to first- or second-generation TKIs. Osimertinib (AZD9291, TAGRISSO) was recently approved by FDA for metastatic EGFR T790M mutation-positive NSCLC. HM61713, ASP8237, EGF816, and PF-06747775 are still in early clinical development. This article reviews the emerging data regarding third-generation agents against EGFR T790M mutation in the treatment of patients with advanced NSCLC. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 20% |
| United States | 1 | 20% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 229 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 227 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 38 | 17% |
| Researcher | 37 | 16% |
| Student > Bachelor | 34 | 15% |
| Student > Master | 21 | 9% |
| Other | 16 | 7% |
| Other | 38 | 17% |
| Unknown | 45 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 51 | 22% |
| Medicine and Dentistry | 45 | 20% |
| Agricultural and Biological Sciences | 25 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 22 | 10% |
| Chemistry | 17 | 7% |
| Other | 15 | 7% |
| Unknown | 54 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 July 2023.
All research outputs
#8,102,595
of 24,593,959 outputs
Outputs from Journal of Hematology & Oncology
#572
of 1,265 outputs
Outputs of similar age
#109,393
of 306,300 outputs
Outputs of similar age from Journal of Hematology & Oncology
#7
of 30 outputs
Altmetric has tracked 24,593,959 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 1,265 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.3. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,300 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.